CS1 targeted chimeric antigen receptor-modified T cells
US-11730797-B2 · Aug 22, 2023 · US
CS1 targeted chimeric antigen receptor-modified T cells
US12497440B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12497440-B2 |
| Application number | US-202318349678-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 10, 2023 |
| Priority date | Dec 5, 2014 |
| Publication date | Dec 16, 2025 |
| Grant date | Dec 16, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
First claim
Opening claim text (preview).
What is claimed is: 1 . A nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) targeting CS1, wherein the CAR comprises: (a) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 9; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; (b) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 9; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; (c) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 11; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; (d) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 11; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; (e) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 2; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; or (f) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 2; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21. 2 . The nucleic acid molecule of claim 1 , wherein the CAR comprises: (a) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 9; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; (b) a CS1 scFv consisting of the amino acid SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 9; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; (c) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 11; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; (d) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 11; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; (e) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 2; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; or (f) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 2; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21. 3 . A population of human T cells harboring the nucleic acid molecule of claim 1 . 4 . The population of human T cells of claim 3 , wherein at least 20%, 30%, 40%, 50%, 60%, 70% or 80% of the transduced human T cells are central memory T cells. 5 . The population of human T cells of claim 4 , wherein at least 10% or 20% of the transduced central memory T cells are CD4+. 6 . The population of human T cells of claim 4 , wherein at least 10% or 20% of the transduced central memory T cells are CD8+. 7 . The population of human T cells of claim 4 , wherein at least 10% of the central memory T cells are CD4+ and at least 10% are CD8+. 8 . The population of human T cells of claim 7 , wherein at least 30% of the transduced human T cells are central memory T cells. 9 . A population of human T cells harboring the nucleic acid molecule of claim 2 . 10 . The population of human T cells of claim 9 , wherein at least 20%, 30%, 40%, 50%, 60%, 70% or 80% of the transduced human T cells are central memory T cells. 11 . The population of human T cells of claim 10 , wherein at least 10% or 20% of the transduced central memory T cells are CD4+. 12 . The population of human T cells of claim 10 , wherein at least 10% or 20% of the transduced central memory T cells are CD8+. 13 . The population of human T cells of claim 10 , wherein at least 10% of the central memory T cells are CD4+ and at least 10% are CD8+. 14 . The population of human T cells of claim 13 , wherein at least 30% of the transduced human T cells are central memory T cells.
Assignees
Inventors
Classifications
Genetically modified cells · CPC title
Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK] · CPC title
Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg · CPC title
- C12N5/0636Primary
T lymphocytes · CPC title
Hinge · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12497440B2 cover?
- Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0636. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).